Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer

Nanomedicine

Volumn 8, Issue 2, 2013, Pages 193-201

  Paolino, Donatella ^a,b   Cosco, Donato ^a   Celano, Marilena ^a   Moretti, Sonia ^c   Puxeddu, Efisio ^c   Russo, Diego ^a   Fresta, Massimo ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UOC Farmacia Ospedaliera   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

gemcitabine; improved anticancer activity; nanocapsule; polylactic acid

Indexed keywords

GEMCITABINE; GLYCEROPHOSPHOETHANOLAMINE; MACROGOL; NANOCAPSULE; POLYLACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BIOCOMPATIBILITY; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN HT29; CELL VIABILITY; COLLOID; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TUMOR XENOGRAFT; ZETA POTENTIAL;

EID: 84873596595     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.101     Document Type: Article

References (26)

1. Subbiah R, Veerapandian M, Yun KS. Nanoparticles: Functionalization and multifunctional applications in biomedical sciences. Curr. Med. Chem. 17, 4559-4577 (2010).
2. Cavallaro G, Licciardi M, Scirè S, Di Stefano M, Giammona G. New pegylated polyaspartamide-based polyplexes as gene delivery vectors. Nanomedicine (Lond.) 5, 243-258 (2010).
3. Jain RK, Stylianopoulus T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010).
4. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: Application of nanotechnology in cancer therapy. Drug Discov. Today 15, 842-850 (2010).
5. Dasanu CA. Gemcitabine: Vascular toxicity and prothrombotic potential. Expert Opin. Drug Saf. 7, 703-706 (2008).
6. Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr. Pharm. Des. 14, 1124-1137 (2008).
7. Paolino D, Cosco D, Racanicchi L et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control. Release 144, 144-150 (2010).
8. Nakano Y, Tanno S, Koizumi K et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96, 457-463 (2007).
9. Cosco D, Bulotta A, Ventura M et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother. Pharmacol. 64, 1009-1020 (2009).
10. Paolino D, Cosco D, Licciardi M, Giammona G, Fresta M, Cavallaro G. Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs. Biomacromolecules 9, 1117-1130 (2008).
11. Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials 31, 7340-7354 (2010).
12. Celano M, Calvagno MG, Bulotta S et al. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 4, 63 (2004).
13. Celia C, Calvagno MG, Paolino D et al. Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes. J. Nanosci. Nanotechnol. 8, 2102-2113 (2008).
14. Pasut G, Canal F, Dalla Via L, Arpicco S, Veronese FM, Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control. Release 127, 239-248 (2008).
15. Stella B, Arpicco S, Rocco F et al. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int. J. Pharm. 344, 71-77 (2007).
16. Couvreur P, Stella B, Reddy LH et al Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6, 2544-2548 (2006).
17. Anderson JM, Shive SS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28, 5-24 (1997).
18. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int. J. Pharm. 385, 113-142 (2010).
19. Schenderlein S, Lück M, Müller BW. Partial solubility parameters of poly(d,l-lactide-co-glycolide). Int. J. Pharm. 286, 19-26 (2004).
20. Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93, 4331-4341 (2008).
21. Mudhakir D, Akita H, Khalil IA, Futaki S, Harashima H. Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice. Drug Metab. Pharmacokinet. 20, 275-281 (2005).
22. Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 50, 6371-6378 (1990).
23. Cosco D, Paolino D, Muzzalupo R et al. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed. Microdevices 11, 1115-1125 (2009).
24. Pereira MA, Furtado VC, Carneiro JM, Spangler M, Andrade G, Nascimento V. PLA-PEG nanocapsules radiolabeled with 99mTechnetium-HMPAO: release properties and physicochemical characterization by atomic force microscopy and photon correlation spectroscopy. Eur. J. Pharm. Sci. 33, 42-51 (2008).
25. Cosco D, Paolino D, Maiuolo J, Russo D, Fresta M. Liposomes as multicompartimental carriers for the multidrug delivery in anticancer chemotherapy. Drug Deliv. Transl. Res. 1, 66-75 (2011).
26. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int. J. Pharm. 422, 229-237 (2012).